SINGLE-CENTER, OPEN-LABEL, SINGLE-DOSE STUDY OF THE EXCRETION BALANCE, PHARMACOKINETICS, AND METABOLISM OF 14C-LABELED UCB0599 AND UCB2713

UCB1332 is a new investigational compound that may eventually be used for the
treatment of Parkinson*s disease. Alpha synuclein is a protein that is present
in the human body, especially in the brain where it plays a role in processes
in the brain cell and in communication between brain cells. In patients with
Parkinson*s disease, accumulation of this protein takes place which disturbs
the normal processes in and between brain cells. UCB1332 interacts with alpha
synuclein and thereby prevents the accumulation of the protein and is therefore
considered to reduce the intensity of the symptoms of Parkinson*s disease.
UCB1332 is in development and is not registered as a drug but has been given to
humans before.

The purpose of the study is to investigate how quickly and to what extent
UCB0599 and UCB2713 are absorbed, distributed, metabolized (broken down) and
excreted from the body (this is called pharmacokinetics). Since UCB0599 and
UCB2713 will be radiolabeled in Parts A and B, UCB0599 and UCB2713 can be
traced in blood (Parts A and B), cerebrospinal fluid (Part B only), and urine
and feces (Part A only). Another purpose in both Parts A and B of the study is
to investigate to what extent the administered study compounds are tolerated.

Part A:
The study will consist of 1 period during which the volunteers will stay in the
research centre from Day -1 to at least Day 8. If on Day 8, the radioactivity
levels in the urine and feces are above pre-defined levels, the volunteers will
have to stay in the clinical research center, and the radioactivity levels in
the urine and feces will be checked every day until a maximum of Day 11.

Part B:
The study will consist of 1 period during which the volunteers will stay in the
clinical research center from Day -1 to Day 3. It may be decided by the medical
doctor that the volunteer will need to stay in the clinical research center for
a longer period of time.

The study will be performed in 2 parts in a total of 14 healthy male
volunteers.

Part A will consist of 8 volunteers. All 8 volunteers will receive 30
milligrams UCB1332 as 2 oral capsules. 4 volunteers in Group 1, 1 of the 2
capsules with UCB1332 will also contain a small dose of 20 micrograms of
UCB0599 which will be labeled with 14-Carbon. For the 4 volunteers in Group 2,
1 of the 2 capsules with UCB1332 will also contain a small dose of 20
micrograms of radiolabeled UCB2713.

Part B will consist of 6 volunteers; 3 volunteers will receive 30 milligrams
UCB1332 and a small dose of 20 micrograms of 14C UCB0599 as an intravenous
infusion. 3 volunteers will receive 30 milligrams UCB1332 and a small dose of
20 micrograms of 14C UCB2713 as an infusion in a vein.

Please refer to the protocol and IB for treatment related adverse events.

Adverse events related to procedures: Pain, minor bleeding, bruising and
possible infection